Literature DB >> 33088813

Prescribing Habits for Androgenic Alopecia among Dermatologists in Spain in 2019-2020: A Cross-Sectional Study.

Cristina Pindado-Ortega1,2, David Saceda-Corralo1,2, Diego Fernández-Nieto1, Juan Jiménez-Cauhé1, Daniel Ortega-Quijano1, Óscar M Moreno-Arrones1,2, Sergio Vañó-Galván1,2.   

Abstract

BACKGROUND: In 2017, we carried out a cross-sectional study with the aim of describing androgenic alopecia (AGA) prescription habits among dermatologists who practice in Spain. Three years later, we repeated this study with the aim of describing the current situation and comparing it with previous data.
MATERIAL AND METHODS: Descriptive cross-sectional study using online questionnaires autocompleted by dermatologists working in Spain.
RESULTS: The responses of 243 dermatologists were analyzed. The most common treatments prescribed for MAGA were topical minoxidil (100%), oral finasteride (92.6%), oral dutasteride (75.7%), and oral minoxidil (50.6%). For premenopausal female AGA (FAGA), the most common treatments were topical minoxidil (99%), oral contraceptives (75%), nutricosmetics (71%), and oral minoxidil (67.9%). Lastly, the most common treatments prescribed in patients with postmenopausal FAGA were topical minoxidil (99.2%), oral finasteride (79%), oral durasteride (71.6%), and oral minoxidil (63%).
CONCLUSIONS: In conclusion, AGA is the most frequent alopecia in the trichology clinic. The most common treatments prescribed in male AGA (MAGA) and postmenopausal FAGA were topical minoxidil and oral finasteride, while in premenopausal FAGA, topical minoxidil, oral contraceptives, and nutricosmetics were most commonly prescribed. In the past three years, oral dutasteride and oral minoxidil have increased drastically among the most prescribed therapies for MAGA, premenopausal FAGA, and postmenopausal FAGA.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Dutasteride; Pattern hair loss; Hair; Hair loss; Minoxidil

Year:  2020        PMID: 33088813      PMCID: PMC7548838          DOI: 10.1159/000509063

Source DB:  PubMed          Journal:  Skin Appendage Disord        ISSN: 2296-9160


  6 in total

1.  Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia.

Authors:  Juan Jimenez-Cauhe; David Saceda-Corralo; Rita Rodrigues-Barata; Angela Hermosa-Gelbard; Oscar M Moreno-Arrones; Diego Fernandez-Nieto; Sergio Vaño-Galvan
Journal:  J Am Acad Dermatol       Date:  2019-05-02       Impact factor: 11.527

2.  Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study.

Authors:  C Pindado-Ortega; D Saceda-Corralo; D Buendía-Castaño; P Fernández-González; Ó M Moreno-Arrones; P Fonda-Pascual; A Alegre-Sánchez; A R Rodrigues-Barata; S Vañó-Galván
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2018-04-12

3.  Oral bicalutamide for female pattern hair loss: A pilot study.

Authors:  Diego Fernandez-Nieto; David Saceda-Corralo; Rita Rodrigues-Barata; Angela Hermosa-Gelbard; Oscar Moreno-Arrones; Juan Jimenez-Cauhe; Daniel Ortega-Quijano; Sergio Vano-Galvan
Journal:  Dermatol Ther       Date:  2019-10-10       Impact factor: 2.851

4.  Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation.

Authors:  Rodrigo Pirmez; Corina-Isabel Salas-Callo
Journal:  J Am Acad Dermatol       Date:  2019-09-11       Impact factor: 11.527

5.  Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.

Authors:  Rodney D Sinclair
Journal:  Int J Dermatol       Date:  2017-12-12       Impact factor: 2.736

6.  Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia.

Authors:  David Saceda-Corralo; Ana Rita Rodrigues-Barata; Sergio Vañó-Galván; Pedro Jaén-Olasolo
Journal:  Int J Trichology       Date:  2017 Jul-Sep
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.